Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains

被引:0
作者
Corentin Deckers
Florian Bélik
Olivier Denis
Isabel Montesinos
Pierre Bogaerts
Jerina Boelens
Laetitia Brassinne
Julie Descy
Stefanie Desmet
Sarah Gils
Bénédicte Lissoir
Koen Magerman
Veerle Matheeussen
Cécile Meex
Hector Rodriguez Villalobos
Anne Marie Van den Abeele
Kris Vernelen
Pieter-Jan Ceyssens
Te-Din Huang
机构
[1] CHU UCL Namur,Laboratory of Clinical Microbiology
[2] UCLouvain,Laboratory of Clinical Microbiology
[3] Site Godinne,Laboratory of Clinical Microbiology
[4] UZ Gent,Laboratory of Clinical Microbiology
[5] Cliniques de L’Europe,Laboratory of Clinical Microbiology
[6] Clinique André Renard,Laboratory of Clinical Microbiology
[7] UZ Leuven,Laboratory of Clinical Microbiology
[8] Medisch Centrum Huisartsen,Laboratory of Clinical Microbiology
[9] Grand Hôpital de Charleroi,Laboratory of Clinical Microbiology
[10] Jessa Ziekenhuis,Laboratory of Clinical Microbiology
[11] UZ Antwerp,Laboratory of Clinical Microbiology
[12] CHU de Liège,Laboratory of Clinical Microbiology
[13] Cliniques Universitaires Saint-Luc,undefined
[14] UCLouvain,undefined
[15] AZ Sint-Lucas,undefined
[16] Quality of Laboratories,undefined
[17] Sciensano,undefined
[18] Unit of Human Bacterial Diseases,undefined
[19] Sciensano,undefined
来源
European Journal of Clinical Microbiology & Infectious Diseases | 2023年 / 42卷
关键词
Temocillin; Antimicrobial susceptibility testing; EUCAST Breakpoints;
D O I
暂无
中图分类号
学科分类号
摘要
Accurate susceptibility result of temocillin (TMO) is important for treating infections caused by multidrug-resistant Enterobacterales. This multicenter study aimed to investigate the performance of routine temocillin testing assays against Enterobacterales challenging strains. Forty-seven selected clinical isolates were blindly analyzed by 12 Belgian laboratories using VITEK® 2 (n = 5) and BD Phoenix™ (n = 3) automated systems, ETEST® gradient strip (n = 3), and disk (3 brands) diffusion method (DD; n = 6) for temocillin susceptibility using standardized methodology. Results were interpreted using EUCAST 2023 criteria and compared to the broth microdilution (BMD; Sensititre™ panel) method used as gold standard. Methods’ reproducibility was assessed by testing 3 reference strains in triplicate. A total of 702 organism-drug results were obtained against 33 TMO-susceptible and 14 TMO-resistant isolates. Excluding Proteae species (P. mirabilis and M. morganii), the essential agreement rates were excellent (91.5–100%) for all MIC-based methods. The highest category agreement was achieved by ETEST® (97.5%) followed by VITEK® 2 (93.2%), disk diffusion (91.6%), and BD Phoenix™ (88.5%). BD Phoenix™ and paper disk diffusion overcalled resistance (11.5% and 6.8% of major discrepancies, respectively), while ROSCO tablets diffusion and VITEK® 2 generated higher very major discrepancies (7.1% and 4.2% respectively). Inter-assay reproducibility was unsatisfactory using recommended E. coli ATCC 25922 strain but was excellent with E. coli ATCC 35218 and K. pneumoniae ATCC 700603 strains. This interlaboratory study suggests that routine testing methods provide accurate and reproducible TMO categorization results except for Proteae species.
引用
收藏
页码:1477 / 1483
页数:6
相关论文
共 16 条
  • [1] Fuchs PC(1985)Interpretive criteria for temocillin disk diffusion susceptibility testing Eur J Clin Microbiol 4 30-33
  • [2] Alexandre K(2021)Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study J Antimicrob Chemother 76 784-788
  • [3] Giske CG(2021)Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study J Antimicrob Chemother 76 1949-1950
  • [4] Alexandre K(2021)Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study-authors’ response J Antimicrob Chemother 76 1950-1951
  • [5] Caron F(2021)Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis JAC Antimicrob Resist 3 dlab005-129
  • [6] Heard KL(2022)Multicentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains J Glob Antimicrob Resist 28 125-15
  • [7] Deckers C(2015)Establishing quality control ranges for temocillin following CLSI-M23-A3 guideline Acta Clin Belg 70 11-2689
  • [8] Maurissen W(2022)Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study JAC Antimicrob Resist 4 dlac086-1853
  • [9] Oosterbos J(2013)Temocillin disc diffusion susceptibility testing by EUCAST methodology J Antimicrob Chemother 68 2688-1686
  • [10] Vanstone GL(2018)Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods J Antimicrob Chemother 73 1848-undefined